Clear-cell renal cell carcinoma (ccRCC) is one of the most common malignancies in humans and is usually associated with poor outcomes. Cancers are considered to be genetic diseases. Therefore, a better understanding of genetic alterations that are related to disease progression or poor prognosis can help to more precisely identify high-risk patients and treat them more effectively. The aim of this study was to examine the frequency of whole chromosome 9 loss (monosomy of chromosome 9) and its prognostic value in patients with ccRCC.
Single nucleotide polymorphism-based chromosome microarray (CMA) analysis was performed on 103 resected specimens from patients with ccRCC who had undergone partial or radical nephrectomy between January 2002 and March 2017 at Fox Chase Cancer Center. Monosomy 9 was correlated with clinicopathologic parameters and recurrence-free survival.
Chromosome 9 loss was detected in 31 (30%) of 103 tumors. Tumors with chromosome 9 loss had higher histologic grade (3 and 4; P < .001) and pathologic stage (P < .001). In 59 patients with non-metastatic ccRCC, chromosome 9 loss was also associated with higher recurrence rate and shorter recurrence-free survival (RFS) (12-month RFS, 77.8%; 95% confidence interval, 36.5%-93.9% for chromosome 9 loss vs. 95.7%; 95% confidence interval, 84.0%-98.9% for no loss; P = .002).
Chromosome 9 loss was found in 30% of patients with ccRCC and correlated with higher grade, advanced stage, and shorter RFS in patients with Stage I to III ccRCC.
Clinical genitourinary cancer. 2019 Sep 26 [Epub ahead of print]
Reza Nejati, Shuanzeng Wei, Robert G Uzzo, Sahar Poureghbali, Jianming Pei, Jacqueline N Talarchek, Karen Ruth, Essel Dulaimi, Alexander Kutikov, Joseph R Testa, Tahseen Al-Saleem
Department of Pathology, Fox Chase Cancer Center, Temple Health System, Philadelphia, PA. Electronic address: ., Department of Pathology, Fox Chase Cancer Center, Temple Health System, Philadelphia, PA., Division of Urologic Oncology, Fox Chase Cancer Center, Temple Health System, Philadelphia, PA., Genomics Facility, Fox Chase Cancer Center, Temple Health System, Philadelphia, PA., Biostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Temple Health System, Philadelphia, PA., Cancer Biology Program, Fox Chase Cancer Center, Temple Health System, Philadelphia, PA.